🎯
LATEST VERIFIED ALGORITHMIC EXECUTION
Quantitative engine captured a net profit of +19.26% on $OC in just 23h 32m.
CRI
$CRIS
🔒 US EquitiesCuris Inc
AVG HISTORICAL GAP
+0.37%
MAX GAP RECORD
+12.78%
🔒 PRO INSTITUTIONAL
AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡
SENTINEL HISTORICAL GAP VIEWER
// $CRIS
📊 1-YEAR TIMELINE (GAPS PLOTTED)
🔮 SIMULATE SETUP 🔒
GAP INSPECTION // PLAYBACK PROTOCOL
$CRIS
HISTORICAL GAP OCCURRENCE
Analyzing price jump between T-1 close and opening auction.
EVENT DATE—
GAP MAGNITUDE—
T-1 CLOSE—
OPEN PRICE—
AI DIRECTIONPRO ONLY 🔒
Bullish Opening Gap
Bearish Opening Gap
T-1 Close Baseline
CATALYSTS & GAP HISTORY
| Aug 14, 2026 Earnings Release 2026-08-14 (AFTER CLOSE) |
+12.78%
|
| May 12, 2026 Earnings Release 2026-05-12 (AFTER CLOSE) |
-3.64%
|
| Mar 19, 2026 Earnings Release 2026-03-19 (AFTER CLOSE) |
+0.00%
|
| Nov 06, 2025 Earnings Release 2025-11-06 (AFTER CLOSE) |
-7.53%
|
| Aug 05, 2025 Earnings Release 2025-08-05 (BEFORE OPEN) |
+6.88%
|
| May 06, 2025 Earnings Release 2025-05-06 (BEFORE OPEN) |
-1.63%
|
| Nov 14, 2024 Earnings Release 2024-11-14 (BEFORE OPEN) |
+0.00%
|
| Aug 01, 2024 Earnings Release 2024-08-01 (BEFORE OPEN) |
+0.00%
|
VOLATILITY & GAP BIAS
AVG GAP MOVE
5.0%
Bullish Gaps (5)
Bearish Gaps (5)
Neutral / Flat (0)
📖 Intelligence Summary
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule…
NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗